Tarceva first-line in EGFR Mut+ NSCLC
Tarceva is indicated for the first-line treatment of patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations1
Tarceva in the post-platinum setting
- Tarceva is indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based first-line chemotherapy1
- Tarceva is also indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen1
- Tarceva® (erlotinib) Summary of Product Characteristics, F. Hoffmann-La Roche Ltd., 2011.